Selection of replacement therapy for patients with severe factor VII deficiency.
The risk of significant bleeding in patients with severe Factor VII (FVII) deficiency is well documented. However, controversy regarding management exists not only for the choice of FVII replacement product, but also for the desired hemostatic level of FVII. Two case reports are presented where fresh frozen plasma (FFP) and several Factor IX (FIX) complex concentrates were used to achieve hemostasis. Significantly higher FVII levels were achieved with Proplex (FIX Complex, Hyland Therapeutics) than with other products. Although this and other reports indicate that minor bleeding can be controlled with levels of FVII under 15%, life-threatening hemorrhages require higher FVII levels that can be attained only by using a product with a significant FVII content. It is important to know the FVII content of FIX concentrates in order to plan appropriate therapy for patients with FVII deficiency.
D001779:Blood Coagulation Factors / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000008:administration & dosage; D005167:Factor VII / Q000008:administration & dosage*; D005168:Factor VII Deficiency / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D011517:Prothrombin Time
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005167:Factor VII; D005164:Factor IX